Contingency Management, Methamphetamine Use Disorder
Conditions
Keywords
Contingency management, Methamphetamine Use Disorder, Contingency management during acute hospitalization, Contingency management in Trauma Injured Patients
Brief summary
This clinical trial is to implement contingency management (CM) as an intervention tool to address methamphetamine use and will be initiated during inpatient acute hospitalization in trauma injured patients. The goals are: * Gather effectiveness data on a CM program for participants in Hawaii who use methamphetamine during hospitalization and following discharge due to trauma injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. * To assess the rate of leaving against medical advice (AMA) and treatment completion in acute hospital setting in participants. * To assess the optimal timing of CM initiation for traumatically injured hospitalized patients by comparing patient outcomes (i.e. duration of CM participation and rates of CM program completion and providing negative urine samples) to NCT06532370 where CM was initiated after discharge from the hospital. For total of 12 weeks, participants will: * Be visited on Mondays/Thursdays or Tuesdays/Fridays by the research team to complete urine analysis during the hospitalization * Visit a follow up clinic up to 2 times per week on Mondays/Thursdays or Tuesdays/Fridays to complete urinalysis following discharge from the hospital * Complete Treatment Effectiveness Assessments at 6 and 12 weeks * Engage in qualitative interview at the end of the CM program
Interventions
BEHAVIORALContingency management
If the urine sample is methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately 50% of the slips offer written praises (i.e. "great job!"). The other 50% of slips are the divided between low value (i.e. food gift cards, bus passes), medium value (i.e. prepaid cellphone, clothing gift cards), and a few large value rewards (i.e. electronic tablet, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date.
Sponsors
Queen's Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants will be assigned to the CM intervention group and for the total of 12 weeks, he/she will be followed up two times a week during the hospitalization and up to three times per week as an outpatient to engage in intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Admitted trauma patients * Age greater than 18 years old * Urine drug screen positive for methamphetamines during the current hospitalization * Report at least weekly methamphetamine use * First methamphetamine use greater than 6 months prior to injury * Report at least 4 Diagnostic and Statistical Manual of Mental Disorders 5th Edition, Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease) * Glasgow Coma Scale ≥13 upon arrival to the emergency department * Ability to understand and participate in study procedures * Ability to communicate in English * Expected discharge date within 45 days on the day of screening / recruitment
Exclusion criteria
* Active psychosis (reporting auditory or visual hallucinations) * Under ongoing cardiorespiratory monitoring * Evidence of moderate or severe traumatic brain injury * Patients who are known to be pregnant * Prisoners * Individuals incarcerated at the time of their hospitalization * Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Effectiveness Assessments (TEA) at 6- and 12-weeks post-enrollment | From enrollment to 6 and 12 weeks | TEA (Treatment Effectiveness Assessment) at 6- and 12-weeks post-enrollment to assess both patient-reported medium-term program effectiveness. TEA asks individuals to respond to changes in four domains following a drug treatment program: Substance use, health, lifestyle, and community. The score for each domain can range from 1 (no change or not much) to 10 (much better), for total score of 4-40. This score allows for the prioritization of each participants values, and therefore does not require strict abstinence to demonstrate benefit from drug treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Conduct qualitative interviews with participants post-program | At the end of the treatment at 12 weeks | Interviews will be conducted as semi-structured qualitative interviews with participants post-program and will be transcribed and analyzed using a Template Analysis approach. Coders will conduct coding of the interview data to ultimately identify themes that will be used as the basis for interpretation. The final analysis of the qualitative data will include contrasts and comparisons made across interviews to examine overlaps and divergences across any relevant sub-samples (i.e. sex, age). Results will present thematic patterns, how frequently each code occurs, and any contradictory evidence. This will allow for the identification of common themes and perspectives, which will provide necessary cultural insights and possible adaptations for further implementation efforts. |
Countries
United States
Outcome results
None listed